Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Prepares To Fight Appeal After US Narcan Victory

Four Patents For Naloxone Spray Invalidated By District Court, But Appeal Looms

Executive Summary

Teva has won a US district court victory invalidating four patents protecting the Narcan naloxone nasal spray. However, despite holding FDA approval for a generic, the Israeli firm believes the battle is far from over.

You may also be interested in...



Padagis Introduces Fresh Narcan Rival In US

Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.

Teva Sees Off Emergent’s US Narcan Appeal In ‘A Close Case’

Shortly after agreeing to provide the state of Texas with its generic version of Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray, Teva has secured victory in patent-invalidity proceedings.

Teva And Sandoz Go Head-To-Head On US Narcan

Teva has delivered the launch of the first generic rival to Narcan naloxone 4mg nasal spray in the US. Sandoz has immediately responded with the introduction of an authorized generic.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel